Related Experiment Video
Updated: Feb 18, 2026
07:52
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
20.5K
Surveillance Strategies in Follicular Non-Hodgkin's Lymphoma's Using Molecular and Genetic Markers Improve
Cherian Verghese1, Kapil Meleveedu2, Urja Nagadia1
1Division of Hematology and Oncology, University of Missouri, Columbia, MO.
American Journal of Clinical Oncology
|February 16, 2026
Summary
Identifying molecular markers can help predict early relapses in follicular lymphoma (FL). This allows for selective surveillance, improving cost-effectiveness for patients with this indolent non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Follicular lymphoma (FL) is the most common indolent non-Hodgkin's lymphoma.
- Current therapies improve survival for 80% of FL patients, but 20% experience early relapse or transformation.
- Existing prognostic models (IPI, FLIPI, FLIPI 2) have limitations in predicting FL behavior.
Purpose of the Study:
- To evaluate the utility of molecular and genetic markers in predicting early relapses in follicular lymphoma.
- To develop selective surveillance strategies based on these markers for improved cost-effectiveness.
Main Methods:
- Analysis of molecular and genetic marker prevalence before treatment.
- Identification of markers present in patients experiencing early relapses versus disease transformation.
- Comparison with newer prognostic models like PRIMA23, ICA13, and POD24-PI.
Main Results:
- Over 10 molecular and genetic markers were uniquely identified in relapsed FL patients.
- These markers differed from those found in patients with disease transformation.
- These markers may indicate treatment-resistant clonal remnants.
Conclusions:
- Molecular and genetic markers can predict early relapses in follicular lymphoma.
- A selective surveillance strategy based on these markers is feasible.
- This approach can enhance cost-effectiveness in managing FL patients.
